Presented at the Annual Meeting of the American Epilepsy Society, San Diego, California, November 1990 and published in abstract form in Epilepsia 1990;31:641.
Pharmacokinetics of Felbamate in Pediatric and Adult Beagle Dogs
Version of Record online: 4 AUG 2005
Volume 33, Issue 5, pages 955–960, September 1992
How to Cite
Adusumalli, V. E., Gilchrist, J. R., Wichmann, J. K., Kucharczyk, N. and Sofia, R. D. (1992), Pharmacokinetics of Felbamate in Pediatric and Adult Beagle Dogs. Epilepsia, 33: 955–960. doi: 10.1111/j.1528-1157.1992.tb02206.x
- Issue online: 4 AUG 2005
- Version of Record online: 4 AUG 2005
- Received April 1991; revision accepted February 1992.
Summary: The relative bioavailability and pharmacokinetics of felbamate (FBM) after a single oral dose and after 10 once-daily oral doses of 60 mg/kg were investigated in adult and pediatric dogs of both sexes. The pediatric and adult dogs were aged 4–6 weeks and 1–2 years, respectively. Analysis of variance (ANOVA) was performed on the bioavailability parameters among all groups and between the first and last doses. No sex-related differences in bioavailability and pharmacokinetic parameters were observed. The bioavailability of FBM in pediatric dogs was significantly less as compared with that in adult dogs. Rapid overall elimination of the drug in pediatric dogs appears to be responsible for the lower bioavailability. The bioavailability of FBM after the last dose was also significantly lower than after the first dose for both age groups. No major differences in the rate constant of FBM absorption (ka) and volume of distribution at steady state (VSS) were observed between the two age groups. As with other clinically useful antiepileptic drugs (AEDs), higher doses of FBM may be required in pediatric populations to achieve optimum drug levels, assuming that age-related changes in FBM disposition will also be confirmed in humans.